865536-65-8|4-Oxo-4-HPR|(2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenamide|-范德生物科技公司

4-Oxo-4-HPR

NMR下载 COA and HPLC MSDS下载
names：
(2E,4E,6E,8E)-N-(4-Hydroxyphenyl)-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxocyclohexen-1-yl)nona-2,4,6,8-tetraenamide
CAS号：
865536-65-8
MDL Number：
MF(分子式)： C26H31NO3 MW(分子量)： 405.53
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	4-Oxo-4-HPR
英文别名	4-Oxo-4-HPR; 4 Oxo 4 HPR; 4Oxo4HPR; 3-Keto fenretinide; 4-Oxo Fenretinide; 4-Keto-4-HPR;
CAS号	865536-65-8
Inchi	InChI=1S/C26H31NO3/c1-18(9-14-23-20(3)24(29)15-16-26(23,4)5)7-6-8-19(2)17-25(30)27-21-10-12-22(28)13-11-21/h6-14,17,28H,15-16H2,1-5H3,(H,27,30)/b8-6+,14-9+,18-7+,19-17+
InchiKey	NZVOGZATHCUFRC-KFJFTADJSA-N
分子式 Formula	C26H31NO3
分子量 Molecular Weight	405.53
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	4-Oxo-4-HPR(CAS:865536-65-8):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	4-Oxo-4-HPR is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. It is also a fenretinide metabolite.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Tiberio P, Cavadini E, Cleris L, Dallavalle S, Musso L, Daidone MG, Appierto V. Sodium 4-Carboxymethoxyimino-(4-HPR) a Novel Water-Soluble Derivative of 4-Oxo-4-HPR Endowed with In Vivo Anticancer Activity on Solid Tumors. Front Pharmacol. 2017 Apr 26;8:226. doi: 10.3389/fphar.2017.00226. eCollection 2017. PubMed PMID: 28491037; PubMed Central PMCID: PMC5405676.

[2]Poliakov E, Samuel W, Duncan T, Gutierrez DB, Mata NL, Redmond TM. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1. PLoS One. 2017 Apr 27;12(4):e0176487. doi: 10.1371/journal.pone.0176487. eCollection 2017. PubMed PMID: 28448568; PubMed Central PMCID: PMC5407626.

[3] Lopez-Barcons L, Maurer BJ, Kang MH, Reynolds CP. P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. Int J Cancer. 2017 Jul 15;141(2):405-413. doi: 10.1002/ijc.30706. Epub 2017 May 9. PubMed PMID: 28340497.

[4] Cho HE, Min HK. Analysis of fenretinide and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry and its application to clinical pharmacokinetics. J Pharm Biomed Anal. 2017 Jan 5;13

[5]117-124. doi: 10.1016/j.jpba.2016.09.046. Epub 2016 Sep 29. PubMed PMID: 27701038; PubMed Central PMCID: PMC5231410.

5: Musso L, Tiberio P, Appierto V, Cincinelli R, Cavadini E, Cleris L, Daidone MG, Dallavalle S. Water-soluble derivatives of 4-oxo-N-(4-hydroxyphenyl) retinamide: synthesis and biological activity. Chem Biol Drug Des. 2016 Oct;88(4):608-14. doi: 10.1111/cbdd.12781. Epub 2016 Jun 6. PubMed PMID: 27135197.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开